Smith & Nephew SNATS (NYSE:SNN) Raised to Strong-Buy at Wall Street Zen

Smith & Nephew SNATS (NYSE:SNN) was upgraded by stock analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Sunday.

Several other research analysts have also recently commented on the stock. Royal Bank Of Canada cut shares of Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a report on Monday, December 15th. Canaccord Genuity Group boosted their price target on shares of Smith & Nephew SNATS from $34.00 to $35.00 and gave the company a “hold” rating in a report on Thursday, March 5th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, Smith & Nephew SNATS presently has a consensus rating of “Hold” and a consensus target price of $36.25.

Smith & Nephew SNATS Price Performance

Shares of NYSE SNN opened at $31.69 on Friday. Smith & Nephew SNATS has a 12 month low of $23.91 and a 12 month high of $38.79. The company has a quick ratio of 1.25, a current ratio of 2.57 and a debt-to-equity ratio of 0.60. The business has a fifty day simple moving average of $34.29 and a 200-day simple moving average of $34.42.

Smith & Nephew SNATS (NYSE:SNN) last released its quarterly earnings results on Tuesday, February 17th. The medical equipment provider reported $29.55 earnings per share for the quarter. The company had revenue of $1.60 billion during the quarter. On average, research analysts predict that Smith & Nephew SNATS will post 1.69 earnings per share for the current fiscal year.

Institutional Trading of Smith & Nephew SNATS

Several large investors have recently added to or reduced their stakes in SNN. Garner Asset Management Corp bought a new stake in Smith & Nephew SNATS in the fourth quarter worth approximately $27,000. Arax Advisory Partners raised its holdings in shares of Smith & Nephew SNATS by 142.6% during the 4th quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 569 shares in the last quarter. Advisors Asset Management Inc. bought a new position in shares of Smith & Nephew SNATS during the 4th quarter valued at $36,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Smith & Nephew SNATS in the 3rd quarter valued at $41,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of Smith & Nephew SNATS in the 4th quarter valued at $43,000. 25.64% of the stock is owned by institutional investors.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.